News & Updates

Show Multimedia Only
Enzalutamide plus leuprolide delays metastasis, progression in prostate cancer
Enzalutamide plus leuprolide delays metastasis, progression in prostate cancer
06 May 2026 byStephen Padilla

Prostate cancer patients treated with enzalutamide plus leuprolide have a higher probability of remaining free of distant metastasis, castration resistance, symptomatic progression, and first symptomatic skeletal event (SSE) at 5 years than those treated with leuprolide alone, as shown by the results of the EMBARK study.

Enzalutamide plus leuprolide delays metastasis, progression in prostate cancer
06 May 2026
Ipilimumab plus nivolumab prolongs survival in melanoma with brain metastases
Ipilimumab plus nivolumab prolongs survival in melanoma with brain metastases
05 May 2026
Scalp cooling reduces chemo-induced alopecia in gynaecological cancers
Scalp cooling reduces chemo-induced alopecia in gynaecological cancers
04 May 2026 byKanas Chan

Scalp cooling (or scalp hypothermia) reduces chemotherapy-induced alopecia, alleviates psychological distress, and improves quality of life (QoL) in patients with primary gynaecologic cancers receiving carboplatin plus paclitaxel, the single-centre, randomized controlled CHARM trial has shown. 

Scalp cooling reduces chemo-induced alopecia in gynaecological cancers
04 May 2026